Publications by authors named "C Karanes"
Article Synopsis
- - The drug development for chronic myelomonocytic leukemia (CMML) has lagged behind successes in other related blood diseases, prompting concern among experts.
- - In September 2023, the FDA organized a symposium to address CMML, bringing together regulators and researchers to identify challenges and discuss future strategies for drug development.
- - The discussions focused on issues like clinical trial design, study endpoints, and regulatory considerations to improve therapeutic options for CMML.
Purpose: Crenolanib is a second-generation tyrosine kinase inhibitor with activity against - and -mutant AML. We conducted a trial of crenolanib plus intensive chemotherapy in adults with newly diagnosed -mutant AML.
Methods: Eligible patients were 18 years and older.
Background: Despite recent progress, multiple myeloma remains incurable. Mezigdomide is a novel cereblon E3 ubiquitin ligase modulator with potent antiproliferative and tumoricidal activity in preclinical models of multiple myeloma, including those resistant to lenalidomide and pomalidomide.
Methods: In this phase 1-2 study, we administered oral mezigdomide in combination with dexamethasone to patients with relapsed and refractory myeloma.
Background: Relapsed severe aplastic anaemia is a marrow failure disorder with high morbidity and mortality. It is often treated with bone marrow transplantation at relapse post-immunosuppressive therapy, but under-represented minorities often cannot find a suitably matched donor. This study aimed to understand the 1-year overall survival in patients with relapsed or refractory severe aplastic anaemia after haploidentical bone marrow transplantation.
View Article and Find Full Text PDFArticle Synopsis
- In a study comparing two types of hematopoietic cell transplantation (dUCB and haplo-BMT), results indicated that both treatments had similar progression-free survival, but haplo-BMT showed lower nonrelapse mortality and better overall survival.
- A secondary analysis explored how the experience of transplantation centers with these methods affected patient outcomes, categorizing centers based on their prior number of transplants in the year before the study.
- Findings revealed that haplo-BM centers had significantly lower overall mortality compared to dUCB centers; however, experienced dUCB centers showed no significant difference in mortality compared to haplo-BMT centers, largely due to a higher relapse risk in hap